$SENS
Senseonics Holdings, Inc. Stock $sens

$sens Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000155837024002218 Filed on March 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$5.047M	$8.030M	$22.39M
YoY Change	22.0%	44.14%	36.62%
Cost Of Revenue	$4.712M	$6.941M	$19.30M
YoY Change	26.56%	40.17%	41.25%
Gross Profit	$300.0K	$1.089M	$3.100M
YoY Change	-25.0%	75.93%	14.81%
Gross Profit Margin	5.94%	13.56%	13.85%
Selling, General & Admin	$8.129M	$7.344M	$29.94M
YoY Change	5.33%	-6.43%	-5.35%
% of Gross Profit	2709.67%	674.38%	965.87%
Research & Development	$10.44M	$10.75M	$48.75M
YoY Change	-15.86%	-7.58%	22.74%
% of Gross Profit	3479.33%	987.05%	1572.65%
Depreciation & Amortization	$169.0K	$636.0K	$1.277M
YoY Change	-28.39%	171.79%	29.64%
% of Gross Profit	56.33%	58.4%	41.19%
Operating Expenses	$18.57M	$18.09M	$78.69M
YoY Change	-7.73%	-7.12%	10.29%
Operating Profit	-$18.23M	-$17.00M	-$75.60M
YoY Change	-7.49%	-9.85%	10.17%
Interest Expense	$2.047M	-$194.0K	$11.11M
YoY Change	-56.0%	-100.64%	-40.6%
% of Operating Profit
Other Income/Expense, Net	-$645.0K	$8.000K	$15.21M
YoY Change	-103.07%	-20.0%	-92.78%
Pretax Income	-$18.88M	-$17.19M	-$60.39M
YoY Change	-1525.76%	-248.69%	-142.49%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$18.88M	-$17.19M	-$60.39M
YoY Change	-1525.76%	-248.69%	-142.49%
Net Earnings / Revenue	-374.02%	-214.07%	-269.73%
Basic Earnings Per Share	-$0.03		-$0.11
Diluted Earnings Per Share	-$0.03	-$0.03	-$0.11
COMMON SHARES
Basic Shares Outstanding	530.7M	528.3M	568.0M
Diluted Shares Outstanding	614.6M		568.0M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$98.71M	$109.5M	$109.5M
YoY Change	-27.74%	-29.96%	-24.0%
Cash & Equivalents	$90.54M	$75.71M	$72.95M
Short-Term Investments	$8.169M	$33.75M	$33.75M
Other Short-Term Assets		$5.201M	$5.201M
YoY Change		-26.66%	-26.66%
Inventory	$7.963M	$8.776M	$8.776M
Prepaid Expenses
Receivables		$4.532M	$4.532M
Other Receivables		$2.065M	$2.065M
Total Short-Term Assets	$118.2M	$130.0M	$130.0M
YoY Change	-19.24%	-19.34%	-19.34%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.436M	$1.184M	$6.364M
YoY Change	37.81%	6.47%	53.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Assets		$1.826M	$1.826M
YoY Change		2302.63%	2302.63%
Total Long-Term Assets	$8.339M	$8.190M	$8.190M
YoY Change	-31.63%	-50.28%	-50.28%
TOTAL ASSETS
Total Short-Term Assets	$118.2M	$130.0M	$130.0M
Total Long-Term Assets	$8.339M	$8.190M	$8.190M
Total Assets	$126.5M	$138.2M	$138.2M
YoY Change	-20.2%	-22.21%	-22.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$675.0K	$4.568M	$4.568M
YoY Change	4.49%	990.21%	990.21%
Accrued Expenses		$12.66M	$12.66M
YoY Change		-17.99%	-17.99%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$29.82M	$17.26M	$17.26M
YoY Change	108.86%	-45.17%	-45.17%
LONG-TERM LIABILITIES
Long-Term Debt		$41.20M	$41.20M
YoY Change		-26.94%	-26.94%
Other Long-Term Liabilities	$6.114M	$6.214M	$6.316M
YoY Change	137.34%	131.09%	-88.46%
Total Long-Term Liabilities	$6.114M	$6.214M	$47.51M
YoY Change	137.34%	131.09%	-57.24%
TOTAL LIABILITIES
Total Short-Term Liabilities	$29.82M	$17.26M	$17.26M
Total Long-Term Liabilities	$6.114M	$6.214M	$47.51M
Total Liabilities	$69.90M	$64.77M	$64.77M
YoY Change	23.9%	-54.58%	-54.58%
SHAREHOLDERS EQUITY
Retained Earnings	-$888.1M	-$869.3M
YoY Change	9.98%	7.47%
Common Stock	$530.0K	$530.0K
YoY Change	10.42%	10.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$18.96M	$35.80M	$73.45M
YoY Change
Total Liabilities & Shareholders Equity	$126.5M	$138.2M	$138.2M
YoY Change	-20.2%	-22.21%	-22.21%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$18.88M	-$17.19M	-$60.39M
YoY Change	-1525.76%	-248.69%	-142.49%
Depreciation, Depletion And Amortization	$169.0K	$636.0K	$1.277M
YoY Change	-28.39%	171.79%	29.64%
Cash From Operating Activities	-$20.26M	-$15.07M	-$70.16M
YoY Change	2.09%	-13.34%	5.81%
INVESTING ACTIVITIES
Capital Expenditures	$316.0K	$170.0K	$350.0K
YoY Change	454.39%	198.25%	12.18%
Acquisitions
YoY Change
Other Investing Activities	$25.70M	$36.37M	$90.06M
YoY Change	-14.36%	390.95%	231.19%
Cash From Investing Activities	$25.38M	$36.19M	$89.71M
YoY Change	-15.25%	392.45%	233.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.03M	-1.178M	20.37M
YoY Change	-1343.37%	-111.39%	-51.23%
NET CHANGE
Cash From Operating Activities	-20.26M	-15.07M	-70.16M
Cash From Investing Activities	25.38M	36.19M	89.71M
Cash From Financing Activities	10.03M	-1.178M	20.37M
Net Change In Cash	15.15M	19.95M	39.92M
YoY Change	63.05%	6356.31%	1611.66%
FREE CASH FLOW
Cash From Operating Activities	-$20.26M	-$15.07M	-$70.16M
Capital Expenditures	$316.0K	$170.0K	$350.0K
Free Cash Flow	-$20.58M	-$15.24M	-$70.51M
YoY Change	3.38%	-12.65%	5.84%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2023#FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
CY2023	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2023#FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001616543
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.senseonics.com/20231231#DepositsAndOtherAssetsNoncurrent
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.senseonics.com/20231231#DepositsAndOtherAssetsNoncurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.senseonics.com/20231231#AccruedLiabilitiesAndOtherLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.senseonics.com/20231231#AccruedLiabilitiesAndOtherLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	530364237
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	479637138
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	530364237
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	479637138
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	530364237
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	12000
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	12000
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-37717
CY2023	dei	Entity Registrant Name EntityRegistrantName	SENSEONICS HOLDINGS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1210911
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	20451 Seneca Meadows Parkway
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Germantown
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20876-7005
CY2023	dei	City Area Code CityAreaCode	301
CY2023	dei	Local Phone Number LocalPhoneNumber	515-7260
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	SENS
CY2023	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	357000000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	530668435
CY2023	dei	Auditor Firm AuditorFirmId	185
CY2023	dei	Auditor Name AuditorName	KPMG LLP
CY2023	dei	Auditor Location AuditorLocation	McLean, Virginia
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75709000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35793000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	33747000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	108222000
CY2023Q4	us-gaap	Inventory Net InventoryNet	8776000
CY2022Q4	us-gaap	Inventory Net InventoryNet	7306000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7266000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7428000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	130030000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	161200000
CY2023Q4	sens	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	7006000
CY2022Q4	sens	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	3108000
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	12253000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1184000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1112000
CY2023Q4	us-gaap	Assets Assets	138220000
CY2022Q4	us-gaap	Assets Assets	177673000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4568000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	419000
CY2022Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	15579000
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	20000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17257000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31471000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	41195000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	56383000
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	102000
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	52050000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6214000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2689000
CY2023Q4	us-gaap	Liabilities Liabilities	64768000
CY2022Q4	us-gaap	Liabilities Liabilities	142593000
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	12000
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	12000
CY2023Q4	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	37656000
CY2022Q4	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	37656000
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	37656000
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	37656000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	479637138
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	530000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	480000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	904535000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	806488000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-11000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-678000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-869258000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-808866000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	35796000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2576000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	138220000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	177673000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22390000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16389000
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	19299000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13663000
CY2023	us-gaap	Gross Profit GrossProfit	3091000
CY2022	us-gaap	Gross Profit GrossProfit	2726000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48752000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	39719000
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	29942000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	31634000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-75603000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-68627000
CY2023	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	5362000
CY2022	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	1824000
CY2022	sens	Nonoperating Gain Loss Fair Value Adjustment NonoperatingGainLossFairValueAdjustment	43745000
CY2023	sens	Nonoperating Gain Loss Exchanges NonoperatingGainLossExchanges	14109000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-101000
CY2023	us-gaap	Interest Expense InterestExpense	11110000
CY2022	us-gaap	Interest Expense InterestExpense	18703000
CY2023	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	6648000
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	184221000
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	138000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	202000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-102000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	15211000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	210746000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-60392000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	142119000
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	667000
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-466000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	667000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-466000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-59725000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	141653000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.30
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	567974492
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	467952475
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	567974492
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	618205605
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-185535000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	34174000
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	951000
CY2022	sens	Issued Common Stock For Vested Rsus And Espp Purchase IssuedCommonStockForVestedRsusAndEsppPurchase	133000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	8618000
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2570000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	142119000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-466000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2576000
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7376000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	63645000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3000
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	21002000
CY2023	sens	Issued Common Stock For Vested Rsus And Espp Purchase IssuedCommonStockForVestedRsusAndEsppPurchase	207000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	8673000
CY2023	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2672000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-137000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-60392000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	667000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	35796000
CY2023	us-gaap	Profit Loss ProfitLoss	-60392000
CY2022	us-gaap	Profit Loss ProfitLoss	142119000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1277000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	985000
CY2023	sens	Amortization Of Financing Costs Discounts And Deferred Costs AmortizationOfFinancingCostsDiscountsAndDeferredCosts	4734000
CY2022	sens	Amortization Of Financing Costs Discounts And Deferred Costs AmortizationOfFinancingCostsDiscountsAndDeferredCosts	12164000
CY2023	sens	Fair Value Adjustment Derivative Liability FairValueAdjustmentDerivativeLiability	-6648000
CY2022	sens	Fair Value Adjustment Derivative Liability FairValueAdjustmentDerivativeLiability	-184221000
CY2022	sens	Nonoperating Gain Loss Fair Value Adjustment NonoperatingGainLossFairValueAdjustment	43745000
CY2022	sens	Gains Losses On Extinguishment Of Debt And Gain Loss On Stock Conversion GainsLossesOnExtinguishmentOfDebtAndGainLossOnStockConversion	-101000
CY2023	sens	Nonoperating Gain Loss Exchanges NonoperatingGainLossExchanges	14109000
CY2022	sens	Impairment Of Options ImpairmentOfOptions	-138000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	8673000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	8618000
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	174000
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-5000
CY2023	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	89000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2191000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	478000
CY2023	sens	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	-162000
CY2022	sens	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	1210000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1644000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	989000
CY2023	sens	Increase Decrease In Deposit Assets And Other Assets IncreaseDecreaseInDepositAssetsAndOtherAssets	438000
CY2022	sens	Increase Decrease In Deposit Assets And Other Assets IncreaseDecreaseInDepositAssetsAndOtherAssets	-381000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2297000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-785000
CY2023	sens	Increase Decrease In Accrued Liabilities And Other Current Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities	-1061000
CY2022	sens	Increase Decrease In Accrued Liabilities And Other Current Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities	1462000
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	31000
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-95000
CY2023	sens	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1122000
CY2022	sens	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-757000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-70163000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-66312000
CY2023	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	350000
CY2022	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	312000
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	68537000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	104706000
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	158600000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	131900000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	89713000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	26882000
CY2023	sens	Proceeds From Issuance Of Common Stock Net ProceedsFromIssuanceOfCommonStockNet	7376000
CY2022	sens	Proceeds From Issuance Of Common Stock Net ProceedsFromIssuanceOfCommonStockNet	34174000
CY2023	sens	Proceeds From Exercise Of Stock Options Rs Us And Espp Net ProceedsFromExerciseOfStockOptionsRSUsAndEsppNet	73000
CY2022	sens	Proceeds From Exercise Of Stock Options Rs Us And Espp Net ProceedsFromExerciseOfStockOptionsRSUsAndEsppNet	1084000
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2672000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2570000
CY2022	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	2926000
CY2023	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	24446000
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	355000
CY2023	sens	Proceeds From Issuance Of Warrants Net ProceedsFromIssuanceOfWarrantsNet	14698000
CY2022	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	12000000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20366000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	41762000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	39916000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2332000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35793000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33461000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75709000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35793000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	3678000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	6568000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3831000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2689000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	173000
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	25656000
CY2023	sens	Issuance Of Warrant In Exchange For Phc Notes IssuanceOfWarrantInExchangeForPhcNotes	48564000
CY2023	sens	Issuance Of Warrants For Loan And Security Agreement IssuanceOfWarrantsForLoanAndSecurityAgreement	364000
CY2023	us-gaap	Stock Issued1 StockIssued1	21002000
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">Organization</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Senseonics Holdings, Inc., a Delaware corporation, is a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;"> Senseonics, Incorporated is a wholly owned subsidiary of Senseonics Holdings, Inc. and was originally incorporated on October 30, 1996 and commenced operations on January 15, 1997. Senseonics Holdings, Inc. and Senseonics, Incorporated are hereinafter collectively referred to as the “Company” unless otherwise indicated or the context otherwise requires.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p>
CY2023	us-gaap	Gross Profit GrossProfit	3100000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-869300000
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	109500000
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, recoverability of long-lived assets, deferred taxes and valuation allowances, derivative assets and liabilities, obsolete inventory, warranty obligations, variable consideration related to revenue, allowance for credit losses, depreciable lives of property and equipment, and accruals for clinical study costs, which are accrued based on estimates of work performed under contract. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that it believes are reasonable, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses. Actual results could differ from those estimates; however, management does not believe that such differences would be material.</p>
CY2023Q4	us-gaap	Cash Cash	2756000
CY2022Q4	us-gaap	Cash Cash	1135000
CY2023Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	72953000
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	34658000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75709000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35793000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	0
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	0
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2023	us-gaap	Derivatives Embedded Derivatives DerivativesEmbeddedDerivatives	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><b style="font-weight:bold;">Derivative Financial Instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt;">The Company accounts for conversion options embedded in convertible notes in accordance with ASC Topic 815, Derivatives and Hedging. ASC Topic 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free standing derivative financial instruments. We review the terms of convertible debt issues to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as separate derivative instruments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:10.0pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt;">The fair value of the embedded features are accounted for as a derivative liability in the Company’s consolidated balance sheets and adjusted to fair value each reporting period. The change in fair value of derivatives is recorded as a component of other income (expense) in the Company’s consolidated statements of operations and comprehensive loss.</p>
CY2023	us-gaap	Guarantees Indemnifications And Warranties Policies GuaranteesIndemnificationsAndWarrantiesPolicies	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Product Warranty Obligations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company provides a warranty of one year on its smart transmitters. Additionally, the Company may also replace Eversense system components that do not function in accordance with the product specifications. Estimated replacement costs are recorded at the time of shipment as a charge to cost of sales in the consolidated statement of operations and are developed by analyzing product performance data and historical replacement experience, including comparing actual return management authorizations to revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">At December 31, 2023 and December 31, 2022, the warranty reserve was $0.5 million and $0.8 million, respectively. The following table provides a reconciliation of the change in estimated warranty liabilities for the years ended December 31, 2023 and 2022 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:10.0pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:52.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:52.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;"></span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at beginning of the period</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 781</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 723</p></td></tr><tr><td style="vertical-align:bottom;width:52.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for warranties during the period</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 242</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 166</p></td></tr><tr><td style="vertical-align:bottom;width:52.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Settlements made during the period</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (509)</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (108)</p></td></tr><tr><td style="vertical-align:bottom;width:52.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at end of the period</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 514</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 781</p></td></tr></table>
CY2023	sens	Product Warranty Term ProductWarrantyTerm	P1Y
CY2023Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	500000
CY2022Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	800000
CY2022Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	781000
CY2021Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	723000
CY2023	us-gaap	Standard Product Warranty Accrual Preexisting Increase Decrease StandardProductWarrantyAccrualPreexistingIncreaseDecrease	242000
CY2022	us-gaap	Standard Product Warranty Accrual Preexisting Increase Decrease StandardProductWarrantyAccrualPreexistingIncreaseDecrease	166000
CY2023	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	509000
CY2022	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	108000
CY2023Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	514000
CY2022Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	781000
CY2022	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-67150000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.30
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	567974492
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	467952475
CY2022	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2411337
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	567974492
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	618205605
CY2022	sens	Number Of Geographical Markets NumberOfGeographicalMarkets	2
CY2023	sens	Number Of Geographical Markets NumberOfGeographicalMarkets	2
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22390000
CY2023	sens	Revenue By Geographical Region Percentage RevenueByGeographicalRegionPercentage	1.000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16389000
CY2022	sens	Revenue By Geographical Region Percentage RevenueByGeographicalRegionPercentage	1.000
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1500000
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1700000
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	83951061
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-60392000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	142119000
CY2022	us-gaap	Dilutive Securities DilutiveSecurities	-209269000
CY2023	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-60392000
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	75054983
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12345350
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	33758000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	12000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	33747000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	121153000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	678000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	120475000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	33758000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	33747000
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	33758000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	33747000
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2160000
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1697000
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	5332000
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4057000
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	1284000
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	1552000
CY2023Q4	us-gaap	Inventory Net InventoryNet	8776000
CY2022Q4	us-gaap	Inventory Net InventoryNet	7306000
CY2023Q4	sens	Prepaid Contract Manufacturing Current PrepaidContractManufacturingCurrent	4244000
CY2022Q4	sens	Prepaid Contract Manufacturing Current PrepaidContractManufacturingCurrent	4097000
CY2023Q4	sens	Tax Credits Receivable TaxCreditsReceivable	1793000
CY2023Q4	sens	Prepaid Clinical And Preclinical Costs PrepaidClinicalAndPreclinicalCosts	343000
CY2022Q4	sens	Prepaid Clinical And Preclinical Costs PrepaidClinicalAndPreclinicalCosts	924000
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	272000
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	336000
CY2023Q4	sens	Prepaid Information Technology And Software Costs Current PrepaidInformationTechnologyAndSoftwareCostsCurrent	242000
CY2022Q4	sens	Prepaid Information Technology And Software Costs Current PrepaidInformationTechnologyAndSoftwareCostsCurrent	189000
CY2023Q4	us-gaap	Prepaid Rent PrepaidRent	122000
CY2022Q4	us-gaap	Prepaid Rent PrepaidRent	132000
CY2023Q4	sens	Research And Development ResearchAndDevelopment	95000
CY2022Q4	sens	Research And Development ResearchAndDevelopment	67000
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	73000
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1243000
CY2023Q4	sens	Prepaid Accounting And Audit PrepaidAccountingAndAudit	61000
CY2022Q4	sens	Prepaid Accounting And Audit PrepaidAccountingAndAudit	270000
CY2023Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	20000
CY2022Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	158000
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1000
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	12000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7266000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7428000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3667000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3150000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2483000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2038000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1184000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1112000
CY2023	us-gaap	Depreciation Depreciation	400000
CY2022	us-gaap	Depreciation Depreciation	500000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4799000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4699000
CY2023Q4	sens	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	3846000
CY2022Q4	sens	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	3502000
CY2023Q4	sens	Accrued Contract Manufacturing Costs Current AccruedContractManufacturingCostsCurrent	1457000
CY2022Q4	sens	Accrued Contract Manufacturing Costs Current AccruedContractManufacturingCostsCurrent	2480000
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	704000
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2050000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	673000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1053000
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	514000
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	781000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	368000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	725000
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	301000
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	149000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	27000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	14000
CY2023Q4	sens	Accrued Liabilities And Other Liabilities Including Related Party Current AccruedLiabilitiesAndOtherLiabilitiesIncludingRelatedPartyCurrent	12689000
CY2022Q4	sens	Accrued Liabilities And Other Liabilities Including Related Party Current AccruedLiabilitiesAndOtherLiabilitiesIncludingRelatedPartyCurrent	15453000
CY2023Q2	sens	Tenant Improvement Allowance TenantImprovementAllowance	1300000
CY2023Q2	sens	Lease Modification Increase Decrease Operating Lease Rou Assets LeaseModificationIncreaseDecreaseOperatingLeaseRouAssets	2500000
CY2023Q2	sens	Lease Modification Increase Decrease Operating Lease Liability LeaseModificationIncreaseDecreaseOperatingLeaseLiability	3800000
CY2023	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2023Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	500000
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	800000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5180000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3032000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	368000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	725000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6214000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2689000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6582000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3414000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	912000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	939000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	967000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	996000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1026000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	4908000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	9748000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3166000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6582000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y4M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.085
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.091
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1100000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1000000.0
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	500000
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	400000
CY2023	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3709000
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	7198000
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	203000
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	11110000
CY2022	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	6539000
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	11773000
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	391000
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	18703000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	20399000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	7397000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	19341000
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	47137000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	530364237
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	479637138
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	12000
CY2023	sens	Number Of Voting Classes NumberOfVotingClasses	1
CY2023Q4	sens	Temporary Equity Voting Right Per Share Price TemporaryEquityVotingRightPerSharePrice	1000
CY2023Q4	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	1.24
CY2023Q4	sens	Voting Right Percentage Cap VotingRightPercentageCap	0.290
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13384000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.38
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y8M15D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	449000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.48
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	974000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.98
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1080000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.52
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11779000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.45
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y25D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3589000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.64
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	6000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.46
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1622000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.22
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13740000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.12
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y2M4D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	13740000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	2.12
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	10638000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.52
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y11M19D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.47
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.04
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	5925
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	974285
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1000000.0
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	500000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2100000
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	30000.00
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	30000.00
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.54
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.29
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.31
CY2023	sens	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue	0.27
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	0.51
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	139610000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	133031000
CY2023Q4	sens	Deferred Tax Assets Capitalized Start Up Costs DeferredTaxAssetsCapitalizedStartUpCosts	5721000
CY2022Q4	sens	Deferred Tax Assets Capitalized Start Up Costs DeferredTaxAssetsCapitalizedStartUpCosts	6538000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	15326000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	13121000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	16284000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	8853000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1684000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1695000
CY2023Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	22000
CY2022Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	5136000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3181000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2143000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	181828000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	170517000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	179517000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	163255000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2311000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	7262000
CY2023Q4	sens	Deferred Tax Liability Amortization Right Of Use Asset DeferredTaxLiabilityAmortizationRightOfUseAsset	1774000
CY2022Q4	sens	Deferred Tax Liability Amortization Right Of Use Asset DeferredTaxLiabilityAmortizationRightOfUseAsset	896000
CY2023Q4	sens	Deferred Tax Liability Amortization Of Debt Discount DeferredTaxLiabilityAmortizationOfDebtDiscount	537000
CY2022Q4	sens	Deferred Tax Liability Amortization Of Debt Discount DeferredTaxLiabilityAmortizationOfDebtDiscount	6366000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2311000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	7262000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	16300000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	16800000
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	656900000
CY2023Q4	sens	Operating Loss Carryforwards Subject To Expiry OperatingLossCarryforwardsSubjectToExpiry	196400000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0025
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0040
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0383
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0132
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0175
CY2023	sens	Effective Income Tax Rate Reconciliation Nondeductible Expense Debt And Other Issuance Cost Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtAndOtherIssuanceCostPercent	0.0573
CY2022	sens	Effective Income Tax Rate Reconciliation Nondeductible Expense Debt And Other Issuance Cost Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtAndOtherIssuanceCostPercent	-0.3168
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0062
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0200
CY2023	sens	Effective Income Tax Rate Reconciliation Nondeductible Expense Officers Compensation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent	0.0099
CY2022	sens	Effective Income Tax Rate Reconciliation Nondeductible Expense Officers Compensation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationPercent	-0.0168
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.0075
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.0021
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2670
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.1171
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3280000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2813000
CY2023	sens	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	-27000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	617000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	505000
CY2023	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	38000
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	38000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3832000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3280000
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	52050000
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	224037000
CY2023	sens	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Conversion Of Financial Instruments FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfFinancialInstruments	1109000
CY2022	sens	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Conversion Of Financial Instruments FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfFinancialInstruments	25656000
CY2022	sens	Fair Value Measurement With Unobservable Inputs Reconciliation Gain Loss On Fair Value Adjustment FairValueMeasurementWithUnobservableInputsReconciliationGainLossOnFairValueAdjustment	-43745000
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	50839000
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	178425000
CY2022	sens	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Loss On Extinguishment FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLossOnExtinguishment	-101000
CY2022	sens	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Financial Asset Impairment Cost FairValueMeasurementWithUnobservableInputsReconciliationRecurringFinancialAssetImpairmentCost	138000
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	81417000
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	5817000
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	102000
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	52050000
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
sens-20231231_cal.xml	Edgar Link	unprocessable
sens-20231231_def.xml	Edgar Link	unprocessable
sens-20231231_lab.xml	Edgar Link	unprocessable
0001558370-24-002218-index-headers.html	Edgar Link	pending
0001558370-24-002218-index.html	Edgar Link	pending
0001558370-24-002218.txt	Edgar Link	pending
0001558370-24-002218-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sens-20231231.xsd	Edgar Link	pending
sens-20231231x10k.htm	Edgar Link	pending
sens-20231231x10k004.jpg	Edgar Link	pending
sens-20231231xex23d1.htm	Edgar Link	pending
sens-20231231xex31d1.htm	Edgar Link	pending
sens-20231231xex31d2.htm	Edgar Link	pending
sens-20231231xex32d1.htm	Edgar Link	pending
sens-20231231xex97d1.htm	Edgar Link	pending
Show.js	Edgar Link	pending
sens-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
sens-20231231x10k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SENS
Senseonics Holdings, Inc. Stock $sens

2024 Q1 Form 10-K Financial Statement

#000155837024002218 Filed on March 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SENS Senseonics Holdings, Inc. Stock $sens

2024 Q1 Form 10-K Financial Statement

#000155837024002218 Filed on March 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SENS
Senseonics Holdings, Inc. Stock $sens